Allogeneic HPV-specific T cell therapy (PapiVax Biotech)

N/A

Report date: 2024/07/18 14:41:10

Base Information

Drug NameAllogeneic HPV-specific T cell therapy (PapiVax Biotech)
Drug Alias NameAllogeneic HPV-specific Cluster of Differentiation 4 (CD4)+ T Cell Therapy (PapiVax Biotech)
ClassificationCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsUterine Cervical Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPapivax Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesPapivax Biotech Inc
Inactive CompaniesN/A
Active IndicationsUterine Cervical Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A